Pharma Versus Hospitals: 340B Battle Continues
Executive Summary
Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.
You may also be interested in...
340B Drug Discount Fight Moves To States As PhRMA Opposes Louisiana Law
PhRMA points to federal court rulings against HHS’s view that companies cannot limit discounts to contract pharmacies. However, there is a split among district courts and while one appellate court has sided with industry two have yet to issue opinions.
The John Green Effect: Will Industry Be Influenced Again?
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.
Pressure Mounts On Pharma To Act On Environmental Targets
There are growing demands from government officials, investors and employees for the pharmaceutical industry to reduce emissions and waste, and – most of all – make environmental sustainability a core part of its business.